The 6-minute walk test in pulmonary arterial hypertension: How far is enough?

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 5, 2012, Pages 396-397

  Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTACYCLIN; TADALAFIL;

6 MINUTE WALK TEST; CLINICAL EXAMINATION; DRUG EFFICACY; EDITORIAL; HEART FUNCTION TEST; HEMODYNAMICS; HUMAN; LONG TERM CARE; MOLECULARLY TARGETED THERAPY; MORBIDITY; MORTALITY; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

DATA INTERPRETATION, STATISTICAL; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84865832285     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201206-1137ED     Document Type: Editorial

References (16)

1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Tapson VF, Clayton LM, Crow JW; PPH Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301. (Pubitemid 26033085)
2. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
3. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157. (Pubitemid 41653106)
4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo controlled trial. Am J Respir Crit Care Med 2002;165:800-804. (Pubitemid 34229650)
5. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled,multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019.
6. Olschewski H, Higenbottam TW, Naeije R, Simonneau G, Galié N, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329. (Pubitemid 34815354)
7. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-1922.
8. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.
9. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:428-433.
10. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galie N. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:632-643.
11. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute-walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-356.
12. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359. (Pubitemid 39232254)
13. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530.
14. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788. (Pubitemid 34925627)
15. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-1619.
16. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-863. (Pubitemid 41632043)